Abstract
The definition of HLA-specific antibodies in solid organ transplant patients is a necessary tool for recipient selection prior to transplantation and monitoring for rejection post transplant. Solid phase assays can detect both complement fixing and non-complement fixing HLA-specific antibodies. Here we describe a method for determining the presence of complement fixing HLA-specific antibodies using a sensitive solid phase assay.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Patel R, Terasaki PI (1969) Significance of the positive crossmatch test in kidney transplantation. N Engl J Med 280(14):735–739
Smith JD, Danskine AJ, Laylor RM, Rose ML, Yacoub MH (1993) The effect of panel reactive antibodies and the donor specific crossmatch on graft survival after heart and heart-lung transplantation. Transpl Immunol 1(1):60–65
Williams GM, Hume DM, Hudson RP Jr, Morris PJ, Kano K, Milgrom F (1968) “Hyperacute” renal-homograft rejection in man. N Engl J Med 279(12):611–618
McCloskey D, Festenstein H, Banner N et al (1989) The effect of HLA lymphocytotoxic antibody status and crossmatch result on cardiac transplant survival. Transplant Proc 21(1 Pt 1):804–806
Smith JD, Hamour IM, Banner NR, Rose ML (2007) C4d fixing luminex binding antibodies – a new tool for prediction of graft failure after heart transplantation. Am J Transplant 7(122809–15 ):122809–122815
Gupta A, Iveson V, Varagunam M, Bodger S, Sinnott P, Thuraisingham RC (2008) Pretransplant donor-specific antibodies in cytotoxic negative crossmatch kidney transplants: are they relevant? Transplantation 85(8):1200–1204
Susal C, Ovens J, Mahmoud K et al (2011) No association of kidney graft loss with human leukocyte antigen antibodies detected exclusively by sensitive Luminex single-antigen testing: a Collaborative Transplant Study report. Transplantation 91(8):883–887
Wahrmann M, Exner M, Haidbauer B et al (2005) [C4d]FlowPRA® screening – a specific assay for selective detection of complement-activating anti-HLA alloantibodies. Hum Immunol 66(5):526–534
Wahrmann M, Exner M, Schillinger M et al (2006) Pivotal role of complement-fixing HLA alloantibodies in presensitized kidney allograft recipients. Am J Transplant 6(5 Pt 1):1033–1041
Smith JD, Banner NR, Hamour IM et al (2011) De novo donor HLA-specific antibodies after heart transplantation are an independent predictor of poor patient survival. Am J Transplant 11(2):312–319
Hodges AM, Lyster H, McDermott A, et al (2012) Late antibody-mediated rejection after heart transplantation following the development of de novo donor-specific human leukocyte antigen antibody. Transplantation (Epub ahead of print)
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Smith, J.D., Rose, M.L. (2013). Solid Phase Assay Measuring C4d Deposition to Determine Complement Fixation by HLA-Specific Antibodies. In: Zachary, A., Leffell, M. (eds) Transplantation Immunology. Methods in Molecular Biology, vol 1034. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-62703-493-7_15
Download citation
DOI: https://doi.org/10.1007/978-1-62703-493-7_15
Published:
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-62703-492-0
Online ISBN: 978-1-62703-493-7
eBook Packages: Springer Protocols